- Home
- ENVB vs VRXAW Comparison
ENVB vs VRXAW Comparison
Compare ENVB & VRXAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.40
N/A
Current Price
$0.14
Company Overview
Basic Information| Metric | ENVB | VRXAW |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 9.1M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | ENVB | VRXAW |
|---|---|---|
| Price | $1.40 | $0.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 132.7K | 73.5K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,914,675.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $0.11 |
| 52 Week High | $13.25 | $0.23 |
Technical Indicators
Market Signals| Indicator | ENVB | VRXAW |
|---|---|---|
| Relative Strength Index (RSI) | 36.40 | 42.98 |
| Support Level | $0.60 | $0.11 |
| Resistance Level | $1.58 | $0.20 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 35.19 | 25.68 |
Price Performance
Historical Comparison ENVB
VRXAW
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.